Analyst Research
| Report Title | Price |
|---|---|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: GlobalData
|
$250.00
|
|
Provider: Reuters Investment Profile
|
$20.00
|
|
Provider: Wright Reports
|
$472.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Zhejiang CONBA Pharmaceutical Co., Ltd. Announces FY 2011 Net Profit Outlook In Line With Analysts' Estimate
Zhejiang CONBA Pharmaceutical Co., Ltd. announced that it expects its net profit for fiscal year (FY) 2011 to grow by 45% to 55%, compared to that of FY 2010 (RMB 185,527,183.00). The Company cited the its investment income, increased operating income and changed scope of consolidation as the main reasons for this forecast. According to I/B/E/S Estimates, analysts expect the Company's net profit for fiscal year 2011 to be RMB 281.12 million.
Latest Developments for Zhejiang CONBA Pharmaceutical Co Ltd
Latest Key Developments in Pharmaceuticals
- Valeant Pharmaceuticals International Inc Near Deal To Acquire Bausch & Lomb From Warburg Pincus LLC-Reuters
- Valeant Pharmaceuticals International Inc Near Deal To Acquire Bausch & Lomb-Reuters
- Astec LifeSciences Ltd Recommends Dividend; Announces Appointment Of Statutory Auditors
- J B Chemicals and Pharmaceuticals Ltd Recommends Dividend
- Share this
- Link this
- Digg this
Follow Reuters